The interrelation between diastolic function indexes and interleukin-6 level in patients with metabolic cardiomyopathy

Abstract

Myocardial injury in diabetes mellitus type 2 (DM-2) is associated not only with insulin resistance, hyperinsulinemia and glucose toxicity, but also with the action of anti-inflammatory cytokins, which accelerate the development of atherosclerotic changes. One of the representatives of cytokins is interleukin-6 (IL-6). Its activation is a marker of disease severity and the predictor of development of late cardiovascular complications. However, the extent of IL-6 involvement into the development of diastolic dysfunction, typical for metabolic cardiomyopathy, is not well studied.